A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Inclusion Criteria: All participants: * Male or nonpregnant, nonbreastfeeding female participants. For PsO Participants: * Present with chronic PsO based on a confirmed diagnosis of chronic PsO vulgaris for at least 6 months prior to baseline * Have ≥10% Body Surface Area (BSA) of psoriasis at screening (Visit 1) and baseline * Have both an static Physician's Global Assessment (sPGA) score of ≥3 and Psoriasis Area and Severity Index (PASI) score ≥12 at screening and baseline For PsA Participants * Have a diagnosis of active PsA for at least 6 months (based on a detailed medical history provided by the patient, and a physical exam by the Study Investigator, and/or other evidence such as that provided by joint x-rays, that establishes a history consistent with a diagnosis of active PsA of at least 6 months' duration) and currently meet the Classification for PsA (CASPAR) criteria. * Have active PsA defined as the presence of at least 3/68 tender and at least 3/66 swollen joints, as determined by the Tender and Swollen Joint Count Assessment Form at screening and baseline. * Presence of active PsO or a documented history of psoriasis. Exclusion Criteria: * Have previously completed or withdrawn from this study, participated in any other study with ixekizumab, or have participated in any study investigating other IL-17 antagonists. * Have a history of drug-induced PsO. * Have a known allergy or hypersensitivity to any biologic therapy that would pose an unacceptable risk …